Skip to content

Nuvalent, Inc. NUVL Total Current Liabilities

Total Current Liabilities at other companies

Pfizer logo
PfizerPFE
$34.35B-5.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$67.95M+38.1%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$83.27M+139%
Exelixis logo
ExelixisEXEL
$370.98M-7.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$289.6M+82.6%
Incyte logo
IncyteINCY
$1.49B-13.4%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s total current liabilities?
Nuvalent, Inc. (NUVL) reported total current liabilities of $81.05M in Q1 2026.
How has Nuvalent, Inc.'s total current liabilities changed year-over-year?
Nuvalent, Inc.'s total current liabilities increased by 8.0% year-over-year, from $75.03M to $81.05M.
What is the long-term trend for Nuvalent, Inc.'s total current liabilities?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s total current liabilities has grown at a 83.5% compound annual growth rate (CAGR), from $4.38M to $91.17M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.